SAO PAULO, May 25, 2017 /PRNewswire/ -- The renowned and innovative aesthetic technology company, Thermi®, an Almirall company, announces regulatory clearance to market and distribute ThermiRF® in Brazil. ThermiRF is a temperature-controlled radiofrequency platform used for a wide range of aesthetic applications using the Science of Heat, and the Beauty of Control.
MedSystems, an importer and distributor of medical equipment and technology in Brazil, will be Thermi's newest partner to expand this versatile technology worldwide. MedSystems will be the exclusive distributor of ThermiRF products in this booming cosmetic market. "We are extremely enthusiastic for the opportunity to enter Brazil with Thermi's innovative applications driven by temperature-controlled technology. Through this expansion, we are extending our global reach and expect a high demand from physicians and their patients in such a dynamic and vibrant market. Achieving clearance of new products in Brazil is always a challenging endeavor; this marks another milestone success for us. We look forward to working with the team at MedSystems," says Vladimir Paul-Blanc, President and General Manager of Thermi.
Thermi anticipates strong support from Brazil's leading aesthetic physicians. ThermiRF applications including; ThermiVa®, ThermiSmooth® Face, ThermiRase® and ThermiTight® will broaden services to patients seeking non-surgical aesthetic procedures. Physicians in Brazil can now depend on Thermi's continued innovation and support as a new way to keep customers happy.
For more information please visit: http://www.thermi.com/.
The Thermi flagship product is the ThermiRF®, Temperature Controlled Radiofrequency Generator System, which is FDA cleared for dermatological and general surgical procedures for electrocoagulation and hemostasis, and to create lesions in nervous tissue. ThermiRF, is an advanced technology using finely controlled thermal energy. It is a multi-use platform which uses proprietary hand pieces designed for specific medical applications and promotes increased patient safety and clinical effectiveness, while providing versatile solutions for physicians serving the aesthetic market. The Thermi250™ also employs temperature-controlled radiofrequency using a specially designed thermistor's regulated hand piece, which delivers precise heating to the skin's surface.
For more information, please visit www.thermi.com
Almirall is a global pharmaceutical company with a strong focus in Dermatology and Aesthetics, with the mission of providing valuable medicines and medical devices to you and future generations. Our R&D is focused on Dermatology, with a wide range of programs including key indications. Through our innovative products, agreements and alliances, our work covers the entire drug value chain. Almirall is continually growing as a specialist company in a wide range of skin diseases, in order to cover our customers' unmet needs.
Founded in 1943, headquartered in Barcelona, Spain, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2016, its revenues totaled 859.3 million euros and, with more than 2.000 employees, it has gradually built up a trusted presence across Europe, as well as in the US.
For more information, please visit www.almirall.com.
This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company's control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/thermi-receives-clearance-to-market-thermirf-in-brazil-the-second-largest-world-market-for-aesthetic-treatments-300464068.html